万孚生物收盘下跌1.22%，滚动市盈率19.00倍，总市值101.15亿元

Core Viewpoint - The company Wanfu Biological has reported a decline in revenue and net profit for Q1 2025, while its PE ratio remains significantly lower than the industry average, indicating potential undervaluation in the context of the medical device sector [1][2]. Company Summary - Wanfu Biological's closing stock price is 21.01 yuan, down 1.22%, with a rolling PE ratio of 19.00 times and a total market capitalization of 10.115 billion yuan [1]. - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1]. - As of Q1 2025, nine institutions hold shares in Wanfu Biological, with a total of 81.10 million shares valued at 1.873 billion yuan [1]. Industry Summary - The average PE ratio for the medical device industry is 49.10 times, with a median of 36.43 times, positioning Wanfu Biological at the 46th rank within the industry [1][2]. - The company's Q1 2025 performance shows a revenue of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross margin of 66.67% [2]. - The company has received multiple accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" [1].